Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Ragistomig is a bispecific antibody combining PD-L1 blockade with 4-1BB agonism to enhance T-cell responses. It is undergoing clinical trials for cancer immunotherapy.
仅用于科研。不用于诊断过程。未经明确授权不得转售。